

July 3, 2024

Company name	CellSource Co., Ltd.
Name of representative	Takashi Sawada, Representative Director and CEO
Securities code	4880, Tokyo Stock Exchange, Prime Market
Contact information for inquiries	Katsuji Onishi, Executive Officer and General Manager of Administration Tel: +81-3-6455-5308

## CellSource's Egg Freezing Anshin Bank Service Adopted for Unicharm's Employee Benefit Program

Unicharm Corporation (Representative Director & CEO: Takahisa Takahara, hereinafter "Unicharm") and CellSource Co., Ltd. (Representative Director & CEO: Takashi Sawada, hereinafter "CellSource"), a regenerative medicine related business, announce that CellSource's egg freezing and storage service, "Egg Freezing Anshin Bank," will be adopted by Unicharm's welfare program starting this July.



According to the "Comprehensive Survey on Various Issues Related to Balancing Infertility Treatment and Work"<sup>1</sup> conducted by the Ministry of Health, Labour and Welfare in 2023, more than half of those who have undergone infertility treatment reported that they "balanced work and treatment," indicating that many people continue their social activities while undergoing infertility treatment. On the other hand, about 10% of female respondents answered that they "resigned from their jobs to undergo infertility treatment" or "changed their employment status," indicating that they were forced to reconsider their life plans.

In response to this situation, Unicharm, which operates the menstrual care product brand "Sofy," aims to be a supportive presence for women who wish to conceive. As part of this effort, in November 2023, Unicharm launched the "Sofy Ovulation Timing Check Sheet"<sup>2</sup> to help women check the timing of their ovulation. Additionally, this year, Unicharm announced its new corporate brand essence, "Love Your Possibilities," aiming to create a workplace environment where employees can cherish their potential and work with a spirit of altruism.

In this context, Unicharm has partnered with CellSource, which provides the egg freezing storage service "Egg Freezing Anshin Bank," to establish a system where Unicharm employees and their relatives

within the second degree of kinship can use the “Egg Freezing Anshin Bank” at a special price through CellSource’s affiliated medical institutions.

Through this system, Unicharm and CellSource will support the flexible career and life planning of all employees and their families.

\*1: Ministry of Health, Labour and Welfare, *Survey Results*. Retrieved from [https://www.mhlw.go.jp/stf/newpage\\_39168.html](https://www.mhlw.go.jp/stf/newpage_39168.html) (accessed July 28, 2024)

\*2: Reacts to the “fertility indicator substance” contained in physiological secretions to notify the optimal timing for conception.

## ■ About Egg Freezing Anshin Bank\*



This is a specialized service for the storage of frozen eggs. We are entrusted with the storage of eggs collected and frozen at our partner medical institutions.

We store frozen eggs safely for a long period of time in our well-controlled facilities and dedicated transportation services.

Official Site: <https://ranshi-touketsu.jp/>

\* Egg Freezing Anshin Bank is a trademark of CellSource Co., Ltd.

## About Unicharm Corporation

Since its establishment in 1961, Unicharm has continued to lead the industry by developing new products ahead of the market, making full use of the nonwoven fabric and absorbent material processing and molding technologies it has cultivated over the years. Today, we are expanding our business fields to include baby care products, health care products, and household products, and are developing products and services in approximately 80 countries and regions around the world to support people’s daily lives in such areas as childcare, nursing care, and housework.

Representative Director and CEO: Takahisa Takahara

Location: Sumitomo Fudosan Tokyo Mita Garden Tower, 3-5-19 Mita, Minato-ku, Tokyo

Website: <https://www.unicharm.co.jp/en>

## About CellSource Co., Ltd.

We specialize in advancing the industrialization of regenerative medicine, providing services such as processing

adipose-derived stem cells, synovial-derived stem cells, and blood, as well as offering regulatory compliance support to medical institutions engaged in regenerative medicine. Operating under a Specific Cell Processing Manufacturing License (Facility Number: FA3160006) in accordance with the Act on the Safety of Regenerative Medicine, we have handled over 93,000 cell-related procedures. With a wealth of experience, we strive to offer reliable services to medical institutions and contribute to research and technological development.

Representative Director and CEO: Takashi Sawada

Representative Director and CXO: Masato Tsumamoto

Location: Shibuya Cast 11F, 1-23-21 Shibuya, Shibuya-ku, Tokyo

Website: <https://www.cellsource.co.jp/en/>

*Note: This translation is for reference purposes only and is not guaranteed to be accurate or complete. In the event of any translation error or misunderstanding, the original Japanese version shall prevail.*